speb/financial-data huggingface dataset:
GYRE cash_flow (quarterly, 2025-03-31) — Changes In Cash: 3182000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Common Stock: 87000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 68123000.00
GYRE cash_flow (quarterly, 2025-03-31) — Common Stock Issuance: 509000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 249000.00
GYRE income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 894000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 7035000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Current Assets: 68448000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 805000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 805000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Current Deferred Liabilities: 123000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Current Deferred Revenue: 123000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 18991000.00
GYRE cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: -191000.00
GYRE cash_flow (quarterly, 2025-03-31) — Deferred Tax: -191000.00
GYRE cash_flow (quarterly, 2025-03-31) — Depreciation: 535000.00
GYRE cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 535000.00
GYRE cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 535000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Derivative Product Liabilities: 3413000.00
GYRE income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 101970672.00
GYRE income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.00
GYRE income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 443000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Dueto Related Parties Current: 228000.00
GYRE income_statement (quarterly, 2025-03-31) — EBIT: 2273000.00
GYRE income_statement (quarterly, 2025-03-31) — EBITDA: 2808000.00
GYRE cash_flow (quarterly, 2025-03-31) — Earnings Losses From Equity Investments: 19000.00
GYRE cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 50000.00
GYRE cash_flow (quarterly, 2025-03-31) — End Cash Position: 15045000.00
GYRE cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 1344000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Finished Goods: 3281000.00
GYRE cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -950000.00
GYRE cash_flow (quarterly, 2025-03-31) — Gain Loss On Investment Securities: -2216000.00
GYRE cash_flow (quarterly, 2025-03-31) — Gain Loss On Sale Of PPE: 0.00
GYRE income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: 2255000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: 612000.00
GYRE income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 4955000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 5083000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 20547000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Gross PPE: 29595000.00
GYRE income_statement (quarterly, 2025-03-31) — Gross Profit: 21164000.00
GYRE cash_flow (quarterly, 2025-03-31) — Income Tax Paid Supplemental Data: 3359000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Income Tax Payable: 4873000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Inventory: 7878000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Invested Capital: 68123000.00
GYRE cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: 1967000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 21367000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 21367000.00
GYRE cash_flow (quarterly, 2025-03-31) — Issuance Of Capital Stock: 509000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 780000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 780000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 10340000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Minority Interest: 36179000.00
GYRE income_statement (quarterly, 2025-03-31) — Minority Interests: -1036000.00
GYRE cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 509000.00
GYRE income_statement (quarterly, 2025-03-31) — Net Income: 2698000.00
GYRE income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 2698000.00
GYRE income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 3734000.00
GYRE income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 2698000.00
GYRE income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 2698000.00
GYRE cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 3734000.00
GYRE income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 3734000.00
GYRE cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: -699000.00
GYRE cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 2787000.00
GYRE cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -121000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Net PPE: 23518000.00
GYRE cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -121000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 63040000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 5818000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 905000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 905000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 5818000.00
GYRE income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 553000.00
GYRE income_statement (quarterly, 2025-03-31) — Normalized Income: 881372.00
GYRE balance_sheet (quarterly, 2025-03-31) — Notes Receivable: 2138000.00
GYRE cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -129000.00
GYRE cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: -2197000.00
GYRE income_statement (quarterly, 2025-03-31) — Operating Income: 2273000.00
GYRE income_statement (quarterly, 2025-03-31) — Operating Revenue: 22058000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 87636209.00
GYRE balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: 612000.00
GYRE income_statement (quarterly, 2025-03-31) — Other Gand A: 4955000.00
GYRE income_statement (quarterly, 2025-03-31) — Other Income Expense: 2362000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 5083000.00
GYRE cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 641000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 5556000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 1399000.00
GYRE income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 107000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Other Payable: 5802000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Other Receivables: 230000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 14846000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Payables: 11025000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 18060000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 3000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 8161000.00
GYRE income_statement (quarterly, 2025-03-31) — Pretax Income: 4635000.00
GYRE cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 956000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
GYRE cash_flow (quarterly, 2025-03-31) — Purchase Of Intangibles: -699000.00
GYRE cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -8403000.00
GYRE cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -122000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Raw Materials: 1169000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Receivables: 22518000.00
GYRE income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 894000.00
GYRE income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 535000.00
GYRE income_statement (quarterly, 2025-03-31) — Research And Development: 3095000.00
GYRE income_statement (quarterly, 2025-03-31) — Restructuring And Mergern Acquisition: 0.00
GYRE balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -70755000.00
GYRE cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 11190000.00
GYRE cash_flow (quarterly, 2025-03-31) — Sale Of PPE: 1000.00
GYRE income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 10841000.00
GYRE income_statement (quarterly, 2025-03-31) — Selling General And Administration: 15796000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Share Issued: 87636209.00
GYRE income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
GYRE cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 507000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 68123000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 63040000.00
GYRE income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 438372.00
GYRE income_statement (quarterly, 2025-03-31) — Tax Provision: 901000.00
GYRE income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.19
GYRE balance_sheet (quarterly, 2025-03-31) — Total Assets: 129790000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 68123000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Total Debt: 1585000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 104302000.00
GYRE income_statement (quarterly, 2025-03-31) — Total Expenses: 19785000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 25488000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 61342000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 6497000.00
GYRE income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: 2273000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 4873000.00
GYRE income_statement (quarterly, 2025-03-31) — Total Unusual Items: 2255000.00
GYRE income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 2255000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Work In Process: 3428000.00
GYRE balance_sheet (quarterly, 2025-03-31) — Working Capital: 49457000.00
GYRE income_statement (quarterly, 2025-06-30) — +Operating Expense: 23448000.00
GYRE income_statement (quarterly, 2025-06-30) — +Total Revenue: 26771000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 71000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 24629000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Accumulated Depreciation: -6425000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 161437000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Allowance For Doubtful Accounts Receivable: -235000.00
GYRE cash_flow (quarterly, 2025-06-30) — Asset Impairment Charge: -163000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Available For Sale Securities: 21528000.00
GYRE income_statement (quarterly, 2025-06-30) — Basic Average Shares: 89119344.00
GYRE income_statement (quarterly, 2025-06-30) — Basic EPS: 0.00
GYRE cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 15045000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Buildings And Improvements: 19087000.00
GYRE cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -279000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 1393000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Capital Stock: 91000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 36491000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 54365000.00
GYRE cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: 22351000.00
GYRE cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -3042000.00
GYRE cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 2088000.00
GYRE cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -51000.00
GYRE cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: -2363000.00
GYRE cash_flow (quarterly, 2025-06-30) — Change In Income Tax Payable: 513000.00
GYRE cash_flow (quarterly, 2025-06-30) — Change In Inventory: -954000.00
GYRE cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: -297000.00
GYRE cash_flow (quarterly, 2025-06-30) — Change In Payable: 462000.00
GYRE cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -1901000.00
GYRE cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: 5446000.00
GYRE cash_flow (quarterly, 2025-06-30) — Change In Receivables: -2608000.00
GYRE cash_flow (quarterly, 2025-06-30) — Change In Tax Payable: 513000.00
GYRE cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -289000.00
GYRE cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: -365000.00
GYRE cash_flow (quarterly, 2025-06-30) — Changes In Cash: 21397000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Common Stock: 91000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 92026000.00
GYRE cash_flow (quarterly, 2025-06-30) — Common Stock Issuance: 23000000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Construction In Progress: 391000.00
GYRE income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 1151000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 9654000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Current Assets: 91285000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 622000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 622000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Current Deferred Liabilities: 95000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Current Deferred Revenue: 95000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 16920000.00
GYRE cash_flow (quarterly, 2025-06-30) — Deferred Income Tax: -300000.00
GYRE cash_flow (quarterly, 2025-06-30) — Deferred Tax: -300000.00
GYRE cash_flow (quarterly, 2025-06-30) — Depreciation: 641000.00
GYRE cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 641000.00
GYRE cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 641000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Derivative Product Liabilities: 3201000.00
GYRE income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 102701707.00
GYRE income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.00
GYRE income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 442000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Dueto Related Parties Current: 219000.00
GYRE income_statement (quarterly, 2025-06-30) — EBIT: 2172000.00
GYRE income_statement (quarterly, 2025-06-30) — EBITDA: 2813000.00
GYRE cash_flow (quarterly, 2025-06-30) — Earnings Losses From Equity Investments: 19000.00
GYRE cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 49000.00
GYRE cash_flow (quarterly, 2025-06-30) — End Cash Position: 36491000.00
GYRE cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: 22351000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Finished Goods: 3444000.00
GYRE cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 1809000.00
GYRE cash_flow (quarterly, 2025-06-30) — Gain Loss On Investment Securities: -212000.00
GYRE cash_flow (quarterly, 2025-06-30) — Gain Loss On Sale Of PPE: 1000.00
GYRE income_statement (quarterly, 2025-06-30) — Gain On Sale Of Ppe: -1000.00
GYRE income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: 212000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: 811000.00
GYRE income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 4829000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 4962000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Gross Accounts Receivable: 24864000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Gross PPE: 29826000.00
GYRE income_statement (quarterly, 2025-06-30) — Gross Profit: 25620000.00
GYRE cash_flow (quarterly, 2025-06-30) — Income Tax Paid Supplemental Data: 447000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Income Tax Payable: 1084000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Inventory: 8861000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Invested Capital: 92026000.00
GYRE cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -3042000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Investmentin Financial Assets: 21528000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 21528000.00
GYRE cash_flow (quarterly, 2025-06-30) — Issuance Of Capital Stock: 23000000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 771000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 771000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Machinery Furniture Equipment: 10348000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Minority Interest: 37417000.00
GYRE income_statement (quarterly, 2025-06-30) — Minority Interests: -1134000.00
GYRE cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: 23000000.00
GYRE income_statement (quarterly, 2025-06-30) — Net Income: 442000.00
GYRE income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 442000.00
GYRE income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 1576000.00
GYRE income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 442000.00
GYRE income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 442000.00
GYRE cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 1576000.00
GYRE income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 1576000.00
GYRE cash_flow (quarterly, 2025-06-30) — Net Intangibles Purchase And Sale: -23000.00
GYRE cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: -2781000.00
GYRE cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: -1681000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Net PPE: 23401000.00
GYRE cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -238000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 87064000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 6134000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 884000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Revenue: 884000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 6134000.00
GYRE income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 2602000.00
GYRE income_statement (quarterly, 2025-06-30) — Normalized Income: 293413.80
GYRE balance_sheet (quarterly, 2025-06-30) — Notes Receivable: 499000.00
GYRE cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 2088000.00
GYRE cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: -192000.00
GYRE income_statement (quarterly, 2025-06-30) — Operating Income: 2172000.00
GYRE income_statement (quarterly, 2025-06-30) — Operating Revenue: 26771000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 90822828.00
GYRE balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: 811000.00
GYRE income_statement (quarterly, 2025-06-30) — Other Gand A: 4829000.00
GYRE income_statement (quarterly, 2025-06-30) — Other Income Expense: 66000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 4962000.00
GYRE cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: -91000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 5336000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 1427000.00
GYRE income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: -145000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Other Payable: 5086000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Other Receivables: 230000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 17874000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Payables: 6460000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 16114000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 89000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 2701000.00
GYRE income_statement (quarterly, 2025-06-30) — Pretax Income: 2238000.00
GYRE cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 1032000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Properties: 0.00
GYRE cash_flow (quarterly, 2025-06-30) — Purchase Of Intangibles: -23000.00
GYRE cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -2781000.00
GYRE cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -256000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Raw Materials: 1207000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Receivables: 25358000.00
GYRE income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 1151000.00
GYRE income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 641000.00
GYRE income_statement (quarterly, 2025-06-30) — Research And Development: 3425000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -70313000.00
GYRE cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 0.00
GYRE cash_flow (quarterly, 2025-06-30) — Sale Of PPE: 18000.00
GYRE income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 15194000.00
GYRE income_statement (quarterly, 2025-06-30) — Selling General And Administration: 20023000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Share Issued: 90822828.00
GYRE income_statement (quarterly, 2025-06-30) — Special Income Charges: -1000.00
GYRE cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 906000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 92026000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 87064000.00
GYRE income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 62413.80
GYRE income_statement (quarterly, 2025-06-30) — Tax Provision: 662000.00
GYRE income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.30
GYRE balance_sheet (quarterly, 2025-06-30) — Total Assets: 152646000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 92026000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Total Debt: 1393000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 129443000.00
GYRE income_statement (quarterly, 2025-06-30) — Total Expenses: 24599000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 23203000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 61361000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 6283000.00
GYRE income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: 2171000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 1084000.00
GYRE income_statement (quarterly, 2025-06-30) — Total Unusual Items: 211000.00
GYRE income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 211000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Work In Process: 4210000.00
GYRE balance_sheet (quarterly, 2025-06-30) — Working Capital: 74365000.00
GYRE income_statement (quarterly, 2025-09-30) — +Operating Expense: 22010000.00
GYRE income_statement (quarterly, 2025-09-30) — +Total Revenue: 30564000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 556000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 25877000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -6934000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 167134000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Allowance For Doubtful Accounts Receivable: -182000.00
GYRE cash_flow (quarterly, 2025-09-30) — Asset Impairment Charge: -54000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 20317000.00
GYRE income_statement (quarterly, 2025-09-30) — Basic Average Shares: 90850040.00
GYRE income_statement (quarterly, 2025-09-30) — Basic EPS: 0.04
GYRE cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 36491000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Buildings And Improvements: 19229000.00
GYRE cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -683000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 1165000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Capital Stock: 91000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 40402000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 60049000.00
GYRE cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: 365000.00
GYRE cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -1247000.00
GYRE cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 4676000.00
GYRE cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 483000.00
GYRE cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: -3513000.00
GYRE cash_flow (quarterly, 2025-09-30) — Change In Income Tax Payable: 1536000.00
GYRE cash_flow (quarterly, 2025-09-30) — Change In Inventory: 72000.00
GYRE cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: -236000.00
GYRE cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: 0.00
GYRE cash_flow (quarterly, 2025-09-30) — Change In Payable: 2019000.00
GYRE cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: -1494000.00
GYRE cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: 398000.00
GYRE cash_flow (quarterly, 2025-09-30) — Change In Receivables: -1193000.00
GYRE cash_flow (quarterly, 2025-09-30) — Change In Tax Payable: 1536000.00
GYRE cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -2453000.00
GYRE cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: -4894000.00
GYRE cash_flow (quarterly, 2025-09-30) — Changes In Cash: 3794000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Common Stock: 91000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 101920000.00
GYRE cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 0.00
GYRE balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 844000.00
GYRE income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 1628000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 7955000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Current Assets: 98576000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 626000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 626000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 154000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 154000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 15913000.00
GYRE cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: -531000.00
GYRE cash_flow (quarterly, 2025-09-30) — Deferred Tax: -531000.00
GYRE cash_flow (quarterly, 2025-09-30) — Depreciation: 649000.00
GYRE cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 649000.00
GYRE cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 649000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Derivative Product Liabilities: 3224000.00
GYRE income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 103971546.00
GYRE income_statement (quarterly, 2025-09-30) — Diluted EPS: 0.03
GYRE income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 3610000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Dueto Related Parties Current: 228000.00
GYRE income_statement (quarterly, 2025-09-30) — EBIT: 6926000.00
GYRE income_statement (quarterly, 2025-09-30) — EBITDA: 7575000.00
GYRE cash_flow (quarterly, 2025-09-30) — Earnings Losses From Equity Investments: 19000.00
GYRE cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 117000.00
GYRE cash_flow (quarterly, 2025-09-30) — End Cash Position: 40402000.00
GYRE cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: 365000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Finished Goods: 3321000.00
GYRE cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 3993000.00
GYRE cash_flow (quarterly, 2025-09-30) — Gain Loss On Investment Securities: 23000.00
GYRE cash_flow (quarterly, 2025-09-30) — Gain Loss On Sale Of PPE: 1000.00
GYRE income_statement (quarterly, 2025-09-30) — Gain On Sale Of Ppe: -1000.00
GYRE income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: -23000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 1398000.00
GYRE income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 4319000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 4847000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Gross Accounts Receivable: 26059000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Gross PPE: 30542000.00
GYRE income_statement (quarterly, 2025-09-30) — Gross Profit: 28936000.00
GYRE cash_flow (quarterly, 2025-09-30) — Income Tax Paid Supplemental Data: 687000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Income Tax Payable: 2646000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Inventory: 8854000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Invested Capital: 101920000.00
GYRE cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -1247000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 20317000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 20317000.00
GYRE cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 0.00
GYRE balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 539000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 539000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Machinery Furniture Equipment: 10469000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Minority Interest: 35495000.00
GYRE income_statement (quarterly, 2025-09-30) — Minority Interests: -2326000.00
GYRE cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: 0.00
GYRE income_statement (quarterly, 2025-09-30) — Net Income: 3610000.00
GYRE income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 3610000.00
GYRE income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 5936000.00
GYRE income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 3610000.00
GYRE income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 3610000.00
GYRE cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: 5936000.00
GYRE income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 5936000.00
GYRE cash_flow (quarterly, 2025-09-30) — Net Intangibles Purchase And Sale: -15000.00
GYRE cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: -564000.00
GYRE cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: 315000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Net PPE: 23608000.00
GYRE cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -668000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 97073000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 6714000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 866000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Revenue: 866000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 6714000.00
GYRE income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 7599000.00
GYRE income_statement (quarterly, 2025-09-30) — Normalized Income: 3628674.40
GYRE balance_sheet (quarterly, 2025-09-30) — Notes Receivable: 693000.00
GYRE cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 4676000.00
GYRE cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: 43000.00
GYRE income_statement (quarterly, 2025-09-30) — Operating Income: 6926000.00
GYRE income_statement (quarterly, 2025-09-30) — Operating Revenue: 30564000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 90890381.00
GYRE balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: 1398000.00
GYRE income_statement (quarterly, 2025-09-30) — Other Gand A: 4319000.00
GYRE income_statement (quarterly, 2025-09-30) — Other Income Expense: 703000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 4847000.00
GYRE cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: -61000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 5322000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 1427000.00
GYRE income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 727000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Other Payable: 3704000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Other Receivables: 230000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 19647000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Payables: 7134000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 15089000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Pensionand Other Post Retirement Benefit Plans Current: 44000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 2873000.00
GYRE income_statement (quarterly, 2025-09-30) — Pretax Income: 7629000.00
GYRE cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 50000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Properties: 0.00
GYRE cash_flow (quarterly, 2025-09-30) — Purchase Of Intangibles: -15000.00
GYRE cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -564000.00
GYRE cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -668000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Raw Materials: 1099000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Receivables: 26800000.00
GYRE income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 1628000.00
GYRE income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 649000.00
GYRE income_statement (quarterly, 2025-09-30) — Research And Development: 2363000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -66703000.00
GYRE cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 0.00
GYRE cash_flow (quarterly, 2025-09-30) — Sale Of PPE: 0.00
GYRE income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 15328000.00
GYRE income_statement (quarterly, 2025-09-30) — Selling General And Administration: 19647000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Share Issued: 90890381.00
GYRE income_statement (quarterly, 2025-09-30) — Special Income Charges: -1000.00
GYRE cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 1147000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 101920000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 97073000.00
GYRE income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: -5325.60
GYRE income_statement (quarterly, 2025-09-30) — Tax Provision: 1693000.00
GYRE income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.22
GYRE balance_sheet (quarterly, 2025-09-30) — Total Assets: 159384000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 101920000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Total Debt: 1165000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 137415000.00
GYRE income_statement (quarterly, 2025-09-30) — Total Expenses: 23638000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 21969000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 60808000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 6056000.00
GYRE income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: 6925000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 2646000.00
GYRE income_statement (quarterly, 2025-09-30) — Total Unusual Items: -24000.00
GYRE income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -24000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Work In Process: 4434000.00
GYRE balance_sheet (quarterly, 2025-09-30) — Working Capital: 82663000.00
GYRE income_statement (annual, 2025-12-31) — +Operating Expense: 99681000.00
GYRE income_statement (quarterly, 2025-12-31) — +Operating Expense: 35332000.00
GYRE income_statement (annual, 2025-12-31) — +Total Revenue: 116588000.00
GYRE income_statement (quarterly, 2025-12-31) — +Total Revenue: 37195000.00
GYRE balance_sheet (annual, 2025-12-31) — Accounts Payable: 124000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 124000.00
GYRE balance_sheet (annual, 2025-12-31) — Accounts Receivable: 31078000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 31078000.00
GYRE balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -7576000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -7576000.00
GYRE balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 172047000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 172047000.00
GYRE balance_sheet (annual, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -151000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -151000.00
GYRE cash_flow (annual, 2025-12-31) — Asset Impairment Charge: -63000.00
GYRE cash_flow (quarterly, 2025-12-31) — Asset Impairment Charge: -34000.00
GYRE balance_sheet (annual, 2025-12-31) — Available For Sale Securities: 23516000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Available For Sale Securities: 23516000.00
GYRE income_statement (annual, 2025-12-31) — Basic Average Shares: 89344622.00
GYRE income_statement (quarterly, 2025-12-31) — Basic Average Shares: 91156159.00
GYRE income_statement (annual, 2025-12-31) — Basic EPS: 0.06
GYRE income_statement (quarterly, 2025-12-31) — Basic EPS: -0.02
GYRE cash_flow (annual, 2025-12-31) — Beginning Cash Position: 11813000.00
GYRE cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 40402000.00
GYRE balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 19569000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 19569000.00
GYRE cash_flow (annual, 2025-12-31) — Capital Expenditure: -1923000.00
GYRE cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -140000.00
GYRE balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 939000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 939000.00
GYRE balance_sheet (annual, 2025-12-31) — Capital Stock: 91000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Capital Stock: 91000.00
GYRE balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 37070000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 37070000.00
GYRE balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 52425000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 52425000.00
GYRE cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 24378000.00
GYRE cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 318000.00
GYRE cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -474000.00
GYRE cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: 1848000.00
GYRE cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 1010000.00
GYRE cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -5625000.00
GYRE cash_flow (annual, 2025-12-31) — Change In Account Payable: 13000.00
GYRE cash_flow (quarterly, 2025-12-31) — Change In Account Payable: -433000.00
GYRE cash_flow (annual, 2025-12-31) — Change In Accrued Expense: 946000.00
GYRE cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: 2380000.00
GYRE cash_flow (annual, 2025-12-31) — Change In Income Tax Payable: 44000.00
GYRE cash_flow (quarterly, 2025-12-31) — Change In Income Tax Payable: 261000.00
GYRE cash_flow (annual, 2025-12-31) — Change In Inventory: -3631000.00
GYRE cash_flow (quarterly, 2025-12-31) — Change In Inventory: -1208000.00
GYRE cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: -791000.00
GYRE cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: -283000.00
GYRE cash_flow (annual, 2025-12-31) — Change In Other Working Capital: 25000.00
GYRE cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: 0.00
GYRE cash_flow (annual, 2025-12-31) — Change In Payable: 56000.00
GYRE cash_flow (quarterly, 2025-12-31) — Change In Payable: -173000.00
GYRE cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 1002000.00
GYRE cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 2207000.00
GYRE cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: -206000.00
GYRE cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -509000.00
GYRE cash_flow (annual, 2025-12-31) — Change In Receivables: -11953000.00
GYRE cash_flow (quarterly, 2025-12-31) — Change In Receivables: -9673000.00
GYRE cash_flow (annual, 2025-12-31) — Change In Tax Payable: 44000.00
GYRE cash_flow (quarterly, 2025-12-31) — Change In Tax Payable: 261000.00
GYRE cash_flow (annual, 2025-12-31) — Change In Working Capital: -15554000.00
GYRE cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -9466000.00
GYRE cash_flow (annual, 2025-12-31) — Changes In Account Receivables: -10806000.00
GYRE cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: -4825000.00
GYRE cash_flow (annual, 2025-12-31) — Changes In Cash: 24914000.00
GYRE cash_flow (quarterly, 2025-12-31) — Changes In Cash: -3459000.00
GYRE balance_sheet (annual, 2025-12-31) — Common Stock: 91000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Common Stock: 91000.00
GYRE balance_sheet (annual, 2025-12-31) — Common Stock Equity: 106031000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 106031000.00
GYRE cash_flow (annual, 2025-12-31) — Common Stock Issuance: 23509000.00
GYRE cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 0.00
GYRE balance_sheet (annual, 2025-12-31) — Construction In Progress: 765000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 765000.00
GYRE income_statement (annual, 2025-12-31) — Cost Of Revenue: 5416000.00
GYRE income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 1743000.00
GYRE balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 11805000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 11805000.00
GYRE balance_sheet (annual, 2025-12-31) — Current Assets: 102369000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Current Assets: 102369000.00
GYRE balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 636000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 636000.00
GYRE balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 636000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 636000.00
GYRE balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 111000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 111000.00
GYRE balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 111000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 111000.00
GYRE balance_sheet (annual, 2025-12-31) — Current Liabilities: 18286000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 18286000.00
GYRE cash_flow (annual, 2025-12-31) — Deferred Income Tax: -1109000.00
GYRE cash_flow (quarterly, 2025-12-31) — Deferred Income Tax: -87000.00
GYRE cash_flow (annual, 2025-12-31) — Deferred Tax: -1109000.00
GYRE cash_flow (quarterly, 2025-12-31) — Deferred Tax: -87000.00
GYRE cash_flow (annual, 2025-12-31) — Depreciation: 2520000.00
GYRE cash_flow (quarterly, 2025-12-31) — Depreciation: 695000.00
GYRE cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 2520000.00
GYRE cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 695000.00
GYRE cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 2520000.00
GYRE cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 695000.00
GYRE balance_sheet (annual, 2025-12-31) — Derivative Product Liabilities: 2961000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Derivative Product Liabilities: 2961000.00
GYRE income_statement (annual, 2025-12-31) — Diluted Average Shares: 103180037.00
GYRE income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 91156159.00
GYRE income_statement (annual, 2025-12-31) — Diluted EPS: 0.02
GYRE income_statement (quarterly, 2025-12-31) — Diluted EPS: -0.02
GYRE income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: 5027000.00
GYRE income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -1723000.00
GYRE balance_sheet (annual, 2025-12-31) — Dueto Related Parties Current: 227000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Dueto Related Parties Current: 227000.00
GYRE income_statement (annual, 2025-12-31) — EBIT: 11491000.00
GYRE income_statement (quarterly, 2025-12-31) — EBIT: 120000.00
GYRE income_statement (annual, 2025-12-31) — EBITDA: 14011000.00
GYRE income_statement (quarterly, 2025-12-31) — EBITDA: 815000.00
GYRE cash_flow (annual, 2025-12-31) — Earnings Losses From Equity Investments: 77000.00
GYRE cash_flow (quarterly, 2025-12-31) — Earnings Losses From Equity Investments: 20000.00
GYRE cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: 343000.00
GYRE cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: 127000.00
GYRE cash_flow (annual, 2025-12-31) — End Cash Position: 37070000.00
GYRE cash_flow (quarterly, 2025-12-31) — End Cash Position: 37070000.00
GYRE cash_flow (annual, 2025-12-31) — Financing Cash Flow: 24378000.00
GYRE cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 318000.00
GYRE balance_sheet (annual, 2025-12-31) — Finished Goods: 2894000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Finished Goods: 2894000.00
GYRE cash_flow (annual, 2025-12-31) — Free Cash Flow: -913000.00
GYRE cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -5765000.00
GYRE cash_flow (annual, 2025-12-31) — Gain Loss On Investment Securities: -2668000.00
GYRE cash_flow (quarterly, 2025-12-31) — Gain Loss On Investment Securities: -263000.00
GYRE cash_flow (annual, 2025-12-31) — Gain Loss On Sale Of PPE: 4000.00
GYRE cash_flow (quarterly, 2025-12-31) — Gain Loss On Sale Of PPE: 2000.00
GYRE income_statement (annual, 2025-12-31) — Gain On Sale Of Ppe: -4000.00
GYRE income_statement (quarterly, 2025-12-31) — Gain On Sale Of Ppe: -2000.00
GYRE income_statement (annual, 2025-12-31) — Gain On Sale Of Security: 2707000.00
GYRE income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: 263000.00
GYRE balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 2319000.00
GYRE balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 2319000.00
GYRE income_statement (annual, 2025-12-31) — General And Administrative Expense: 20804000.00